Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00181571 · ClinicalTrials.gov registry record · Phase 4
A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
A Phase 4 study of ADHD, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 297
- Enrollment target
- 1
- Study location
NCT00181571 is a Phase 4 study of ADHD that has completed, run by Massachusetts General Hospital. The registered enrollment target is 297 participants, above the 186-participant average among 75 other ADHD trials with a reported enrollment target (60% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00181571, a Phase 4 study of ADHD, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 297 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) (childhood onset). We hypothesize ADHD symptomatology in adults with DSM-IV ADHD will be responsive to Concerta treatment and Concerta-associated response of ADHD symptomatology in adults will be sustained over time.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG methylphenidate HCl (Concerta)
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2003-06 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00181571
The ClinicalTrials.gov registry entry for NCT00181571 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 75 other ADHD trials with a reported enrollment target (60% higher). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00181571 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00181571 about?
NCT00181571 is a clinical study titled "A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder". This is a double-blind, placebo-controlled study using daily doses of up to 1.3 mg/kg/day of Concerta in the treatment of adults with the DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) (childhood onset). We hypothesize ADHD symptomatology in adults with DSM-IV ADHD will be respo...
What is the current status of trial NCT00181571?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 297 participants. The study started on 2003-06. Estimated completion is 2007-08.
What conditions does trial NCT00181571 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT00181571?
The interventions under investigation include: Placebo (DRUG), methylphenidate HCl (Concerta) (DRUG).
Who is sponsoring clinical trial NCT00181571?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00181571 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
Evaluating Treatment of ADHD in Children with Down Syndrome
RECRUITING · Phase 4
-
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
RECRUITING · Phase 4
-
AWARE: Management of ADHD in Autism Spectrum Disorder
RECRUITING · Phase 4
-
Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom
ACTIVE NOT RECRUITING · Phase 4
-
Evaluation of an Intervention for Improving Community-based Pediatric Attention-Deficit Hyperactivity Disorder (ADHD) Care
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.